What Стимол treats: Main Uses and Benefits

The therapeutic utility of Стимол (Citrulline Malate) is generally centered on its role as an antiaesthenic agent and functional capacity restorer, applied across specific clinical and physiological contexts where fatigue and weakness may interfere with daily functioning. The compound is used in managing asthenia and assisting the recovery of muscle function after acute diseases.

Стимол is commonly used in situations involving symptoms of persistent, non-specific functional asthenia, generalized tiredness, and states of reduced vigor during periods of convalescence. The medication offers symptomatic relief that helps patients cope more steadily when symptoms interfere with routine activities, contributing to easing the overall symptom load.

“The medication is considered relevant when short-term symptomatic assistance is needed to manage symptoms that create noticeable physiological strain.”

This supportive management contributes to improved comfort during periods of heightened symptoms. It is considered relevant in contexts involving heightened systemic burden, such as the post-recovery period after major surgical procedures or infections, and following intense physical effort where muscular fatigue and soreness are present.

Quick Fact: Relief for Functional Asthenia Стимол is applied in conditions characterized by periods of heightened symptoms of weakness and is relevant for managing symptom clusters that may become intense or disruptive.

Who Can and Cannot Use Стимол (Citrulline Malate)

Official regulatory documentation defines the eligible population for Стимол based on age, contraindications, and specific physiological states. The medicine is primarily intended for use by adults and children from 6 years of age. Use is not recommended for children under this minimum age threshold.

Contraindications and Restrictions

Official labeling does not document specific restrictions or dosage adjustments related to hepatic or renal impairment.

The official interaction profile for Стимол (Citrulline Malate) is characterized by a general absence of significant pharmacokinetic restrictions and formally prohibited combinations in regulatory labeling. Citrulline Malate is primarily a metabolic agent, and its interaction pattern is defined by a single documented pharmacodynamic effect, rather than complex changes in drug exposure.

Official Interaction Patterns

Regulatory Constraints and Profile Summary

Regulatory documents do not list any formally contraindicated combinations that prohibit co-administration with Stimol. The absence of specific warnings concerning metabolic or drug transporter activity means that Citrulline Malate does not require mandatory timing separation rules for administration with food or other products. The official regulatory classification of the interactions focuses on the necessary vigilance regarding the potential combined effect on blood pressure, a high-level monitoring recommendation consistent with a profile that lacks significant metabolic or transporter-related drug interaction risks.

Стимол is an organic salt composed of L-citrulline and malate. The L-citrulline component acts as a metabolic precursor, primarily targeting the renal proximal tubules, where it is converted into L-arginine through the citrulline-arginine cycle via the sequential actions of argininosuccinate synthetase and argininosuccinate lyase. This conversion increases systemic L-arginine bioavailability. L-arginine is the substrate for the enzyme nitric oxide synthase (NOS), which catalyzes the production of nitric oxide (NO) in endothelial cells. NO acts as a signaling molecule, diffusing into vascular smooth muscle cells where it activates soluble guanylate cyclase (sGC), increasing the intracellular concentration of cyclic guanosine monophosphate (cGMP). The downstream cascade involves cGMP-dependent protein kinase, leading to reduced intracellular calcium concentration and subsequent smooth muscle relaxation. This action results in systemic vasodilation and increased blood flow to peripheral tissues. Concurrently, L-citrulline facilitates the urea cycle in the liver, promoting the conversion of ammonia into urea, thereby enhancing nitrogenous waste clearance. Malate, the counter-ion, is an intermediate of the tricarboxylic acid (TCA) cycle, contributing to the support of oxidative phosphorylation for adenosine triphosphate (ATP) synthesis.

How to Use Стимол: Administration Guidelines

This section outlines the standardized procedures for administering Стимол (Citrulline Malate), based on prescribing information for its pharmaceutical use. The instructions detail the route, dosing, preparation, and duration of the treatment course.

Administration Scope

Procedural Context

The administration of Citrulline Malate is governed by a precise protocol. The liquid form requires mandatory dilution in water prior to consumption, a key instruction tied directly to proper use. The treatment course is defined as a fixed, short-term duration, which dictates the overall use pattern over time. Furthermore, the guidelines establish separate daily dose counts for adults and children, ensuring age-specific adherence to the established regimen.

Research Evidence / Overview of Studies for Стимол (Citrulline Malate)

Research Evidence for Functional Asthenia and Generalized Tiredness

Стимол (Citrulline Malate) was evaluated in studies exploring symptoms related to functional asthenia and persistent, generalized tiredness. The original evidence base includes short-term Randomized Controlled Trials (RCTs) and various observational studies that were applied in studies examining patient-reported experiences of fatigue. The populations was evaluated in included clinical patients marked by functional limitations and those recovering during a convalescence period.

Researchers focused on outcomes related to systemic or functional imbalance, such as how symptoms changed on self-assessment scales. Studies monitored changes in patient-reported outcomes, such as subjective feelings of tiredness and vigor, based on self-assessment scales. This evidence helps contextualize how patients reported their experience during the study period.

However, the evidence base for this specific, generalized tiredness indication is characterized by limited information for long-term outcomes and a lower number of recent, large-scale international trials. Sample sizes were modest in many of the foundational studies, and findings were mixed regarding the consistency of reported changes across all populations. Therefore, the certainty remains low concerning the application in long-term exploration of chronic functional asthenia.

Research Evidence for Muscular Fatigue and Physical Endurance

Citrulline Malate was evaluated in a separate, extensive body of research related to muscular fatigue and the body’s ability to perform intense exercise. Research examined this aspect primarily through numerous acute and short-term Randomized Controlled Trials (RCTs), and the findings have been aggregated in several systematic reviews and meta-analyses. These studies focused on outcomes monitoring physiological strain or stress related to athletic performance.

The populations was observed in included healthy young adults, resistance-trained individuals (such as athletes), and recreationally active people. Studies monitored objective measures like the total number of repetitions completed during high-intensity exercise and physiological markers associated with metabolic stress. Data show patterns related to measured changes during the study period in metrics like total work performed or the perceived effort required to complete a task.

Nevertheless, follow-up durations were limited in most of this research, which often focused on the immediate, acute response to the substance before or during exercise. The evidence quality varies across studies, and subgroup findings are uncertain, as results can differ significantly based on the training level of the participant and the type of physical activity performed. The effects of long-term supplementation on sustained athletic performance are not fully established.

Understanding Long-Term Studies and Durability of Effect

The research primarily available for Citrulline Malate is focused on short-term symptom changes or studies observing responses over defined time intervals lasting typically two weeks or less, especially in the performance context. Studies related to generalized functional asthenia also often cover short-term or episodic symptom patterns during recovery.

Research does not provide insight into whether individual response patterns are maintained over months or years of use, as trials extending beyond a few weeks are less common. This means that the long-term effects are not fully established, and there is limited information for long-term outcomes related to maintaining functional capacity or continuous relief from chronic symptoms. The research provides insight into short-term changes, but comparative evidence is lacking for extended treatment schedules.

Evidence in Different Populations and Groups Studied

The research base has primarily focused on specific groups. Studies for asthenia was conducted during periods of increased symptom activity mostly in adults, including those undergoing convalescence. For physical endurance, the bulk of the evidence is concentrated in healthy young adults and trained athletes.

Data for certain groups remain insufficient. For instance, there is little published research that was observed in children or adolescents with asthenia. Similarly, subgroup findings are uncertain for older adults or individuals with underlying comorbidities, as results apply only to the populations studied, which are often young and healthy. The evidence available to regulators is part of the research record but does not characterize the response patterns across all potential user groups.

Summary of Evidence Gaps and Areas of Research Uncertainty

Evidence is limited in several key areas, despite the volume of research available, particularly for the generalized asthenia indication. A primary limitation is that follow-up durations were limited, meaning that the durability of any observed response is not fully established. Furthermore, the definition and measurement of the outcomes, such as asthenia, may vary across the studies, leading to findings that were mixed.

Research provides context but not individual predictions. The available data helps contextualize how patients reported their experience under the specific conditions of the trials, but it highlights that certainty remains low in areas where robust, long-term, multi-center RCTs are absent. Research is ongoing in some areas to better understand the short-term measured changes, but the gaps in long-term data and evidence for certain patient groups persist.

Key Studies & References

1. [Autonomic disorders in persons with asthenic syndrome and their correction with citrulline malate].
2. [Use of citrulline malate (stimol) in patients with autonomic dystonia associated with arterial hypotension].
3. Scientific Opinion on the substantiation of a health claim related to citrulline malate and faster recovery from muscle fatigue after exercise pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (European Food Safety Authority Opinion)

Common questions about Стимол (FAQ)

Q: Does taking Стимол affect sleep?

Official documents mention that insomnia, or difficulty sleeping, is described as a possible adverse effect related to the nervous system. This is noted in the official safety documentation detailing possible adverse effects.

Q: Can Стимол be taken long-term?

According to administration guidelines, a standard course of treatment is generally limited to a maximum of four weeks (one month). The existing research base contains limited information for long-term outcomes beyond this period, meaning effects over many months or years are not fully established.

Q: Does Стимол interact with medications for depression or anxiety?

Official regulatory documents focusing on drug-drug interactions do not list specific restrictions related to how Стимол affects the metabolism or transport (pharmacokinetics) of many common medicines, including those for depression or anxiety. The interaction profile is generally defined by effects on blood pressure.

Q: Are there different forms of Стимол available (e.g., liquid, tablet)?

The pharmaceutical form of Стимол is specified as an oral solution, meaning it is a liquid preparation. It is typically supplied in individual, readily measurable unit-dose sachets or ampoules for ingestion.

Q: Is the main active component in Стимол naturally occurring?

The active ingredient, Citrulline Malate, is defined as a derived organic salt. It is formed by combining L-Citrulline, which is classified as a non-essential amino acid, with Malic Acid (Malate).

Q: What does official guidance say about using Стимол if I have diabetes?

Official documents specify that the formulation is typically sugar-free. This characteristic is noted as relevant for individuals monitoring their sugar intake.

Q: Is it necessary to take Стимол with food?

Administration guidelines published in the official documents indicate that the medicine must be taken with meals. This administration condition is specified in the official guidelines.

Q: Is Стимол used for energy or fatigue?

Стимол is pharmacologically classified as an antiaesthenic agent and a metabolic regulator. Its general purpose is defined as supporting the body against the feeling of increased fatigue and recovery from generalized functional asthenia.

Q: Can someone who is physically active use Стимол?

Research evidence has focused on the compound’s effects in populations including healthy young adults and resistance-trained individuals. Studies in this area have primarily examined outcomes related to muscular fatigue and intense physical effort.

Q: Are there any dietary restrictions mentioned in the official information for Стимол?

Official labeling includes a specific caution for patients following a strict hyposodium (salt-free) diet. This is due to the documented sodium content found in the formulation of the medicine.

Q: Why do some people say Стимол helps with recovery?

The general purpose is to support recovery from functional asthenia, with the active component assisting in enhanced clearance of ammonia and supporting cellular ATP synthesis (energy generation). This dual metabolic action provides the context for its use during periods of convalescence.

Q: Has Стимол been studied in research for chronic conditions?

The research base for the product is primarily focused on short-term symptom changes or episodic symptom patterns. Official research reviews note that there is limited information for long-term outcomes regarding chronic symptoms.

Q: Does Стимол have any known effect on blood pressure?

Official safety information notes that a possible transient hypotensive effect (low blood pressure) has been documented as a rare occurrence. Additionally, there is an official caution regarding a risk of additive hypotensive effects if co-administered with certain blood pressure-lowering medications.

Q: Why is Стимол sometimes recommended for intense effort?

Studies have extensively examined the active substance's relationship to muscular fatigue and the ability to perform intense exercise. The malate component is noted to support the tricarboxylic acid (TCA) cycle for adenosine triphosphate (ATP) synthesis, which is relevant to cellular energy pathways.

Q: How does Стимол affect kidney health according to official information?

The mechanism of action involves the active component acting as a precursor that targets the renal proximal tubules and assists the urea cycle to enhance nitrogenous waste clearance. However, official regulatory documents do not document specific restrictions or dosage adjustments related to renal impairment.

Q: What is the typical duration of use mentioned in studies for Стимол?

The majority of the research base involves studies focused on short-term symptom changes or observing responses over defined time intervals. These studies typically last two weeks or less, especially in the context of physical performance.

Q: Are there any warnings about using heavy machinery while taking Стимол?

Official safety warnings advise that caution is recommended when performing tasks that require mental alertness, such as driving or operating machinery. This is advised because of the potential for dizziness or other central nervous system effects documented in the safety profile.

Q: Why do some forums discuss using Стимол for detoxification?

The official mechanism of action explains that the citrulline component facilitates the urea cycle in the liver. This process promotes the conversion of ammonia into urea, thereby enhancing the clearance of nitrogenous waste products.

Q: Does the efficacy of Стимол depend on the underlying condition?

Research reviews indicate that for functional asthenia, findings were mixed regarding consistent reported changes across all observed populations. For physical endurance, official documents note that subgroup findings are uncertain, as reported results have varied based on the participant’s training level.

Q: Is Стимол generally well-tolerated?

The active component is generally described in official sources as having a favorable safety profile with very low toxicity in humans. Reported adverse effects are typically characterized as being mild and transient.

Q: What is the safety profile of Стимол for the liver?

The mechanism of action confirms the active substance is involved in the urea cycle in the liver. Official regulatory documents, however, do not document specific restrictions or dosage adjustments related to hepatic impairment (liver problems).

Q: Are there any known allergic reactions associated with Стимол?

Official safety information notes that rare cases of hypersensitivity or allergic reactions are possible. These reactions may include symptoms such as rash, itching, or swelling.

How to Store and Dispose of Стимол (Citrulline Malate)

Official regulatory documents define specific requirements for storing and disposing of Стимол to maintain the medicine's stability and ensure safety.

Storage Conditions

These conditions are essential to ensure the validity of the product's labeled expiration date. The medicine must not be used after the date printed on the package.

Disposal Instructions

Expired or unused Стимол must be disposed of according to local requirements for pharmaceutical products. It is mandated that the medicine must not be discarded via household waste or wastewater to prevent environmental contamination.